Baseline background therapies for diabetes, hypertension and dyslipidemia
| Antidiabetic background therapy at baseline, n (%) | 20 (100) (Switch) | 5 (100) (Addition) |
| Metformin, n (%) | 15 (75) | 5 (100) |
| SUs, n (%) | 11 (55) | 2 (40) |
| DPP-4 inhibitors, n (%) | 20 (100) | – |
| Sitagliptin, n (%) | 7 (35) | – |
| Teneligliptin, n (%) | 5 (25) | – |
| Alogliptin, n (%) | 3 (15) | – |
| Vildagliptin, n (%) | 3 (15) | – |
| Linagliptin, n (%) | 2 (10) | – |
| α-GIs, n (%) | 4 (20) | 0 |
| Pioglitazone, n (%) | 2 (10) | 0 |
| SGLT2 inhibitors, n (%) | 1 (5) | 0 |